How Iwilfin Works Against High-Risk Neuroblastoma
Iwilfin (eflornithine hydrochloride) treats high-risk neuroblastoma by blocking an enzyme called ornithine decarboxylase (ODC), which limits polyamine production in cancer cells. Polyamines like putrescine, spermidine, and spermine fuel rapid cell growth and survival. By inhibiting ODC, Iwilfin starves neuroblastoma cells of these molecules, slowing tumor regrowth after initial chemotherapy, surgery, and radiation.[1][2]
The drug is FDA-approved for maintenance therapy in patients aged 1 year and older who achieve at least partial response to prior multimodality therapy. Taken orally twice daily as a powder mixed in water or juice, it reduces relapse risk without targeting the cancer directly during active treatment phases.[1]
Clinical Evidence from Trials
Approval stemmed from the phase 3 International Society of Paediatric Oncology European Neuroblastoma Group (SIOP EUNB) study (INT-N5.1), involving 447 children with high-risk neuroblastoma post-induction chemotherapy and consolidation. Patients on oral eflornithine had a 5-year event-free survival (EFS) of 74% versus 64% on observation alone, and overall survival (OS) of 90% versus 84%. Median EFS had not been reached in the eflornithine arm after 4.5 years.[1][3]
This builds on earlier phase 2 data showing eflornithine extended progression-free survival by inhibiting ODC-driven polyamine synthesis in residual microscopic disease.[2]
Who Qualifies and How It's Used
High-risk neuroblastoma is defined by factors like age over 18 months, MYCN amplification, or metastatic disease (stage 4). Iwilfin starts after frontline therapy achieves response and continues for up to 2 years or until relapse/disease progression. It's not curative alone but prevents minimal residual disease from advancing.[1]
Dosing is weight-based: 700 mg/m² twice daily for those ≥10 kg, or 132 mg twice daily for smaller children, with monitoring for diarrhea, neutropenia, or hearing changes.[1]
Common Side Effects and Monitoring
Most patients experience mild issues like decreased appetite (43%), diarrhea (28%), or vomiting (25%). Serious risks include grade 3/4 neutropenia (18%) and infections (14%). Long-term, 11% needed hearing tests due to ototoxicity risk. No deaths linked to the drug occurred in trials.[1][3]
Patients on isotretinoin (often co-administered) face heightened skin dryness or rash risks.
How It Compares to Other Maintenance Options
Unlike isotretinoin, which induces cell differentiation via retinoic acid receptors, Iwilfin specifically disrupts polyamine pathways—a distinct mechanism with complementary effects. The SIOP trial showed dual therapy (eflornithine + isotretinoin) further improved EFS over isotretinoin alone (70% vs. 60% at 3 years in prior studies).[1][4]
No head-to-head trials exist with emerging immunotherapies like dinutuximab beta.
Ongoing Research and Patent Status
Phase 2 trials explore Iwilfin combinations with dinutuximab for frontline maintenance. Pediatric exclusivity runs until July 2029; check DrugPatentWatch.com for detailed patent expirations on eflornithine formulations.[1][5]
[1]: FDA Prescribing Information for Iwilfin (Usana Institute, approved Dec 2023). https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215500s000lbl.pdf
[2]: Maris JM et al. *N Engl J Med* (2018). Phase 2 trial of DFMO in high-risk neuroblastoma.
[3]: Sausen et al. *J Clin Oncol* (2024). SIOP EUNB INT-N5.1 results.
[4]: Matthay KK et al. *N Engl J Med* (2009). Isotretinoin maintenance study.
[5]: DrugPatentWatch.com. Eflornithine patents. https://www.drugpatentwatch.com/p/tradename/IWILFIN